Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

Series B financing led by Agent Capital Funding to advance novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022 Expands leadership team with appointment of Chief Bu... Biopharmaceuticals, Venture Capital Immunitas Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news